An Introduction to Planning for HTA for Tumour-Agnostic Cancer Drugs
Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncological drug development.¹ The advent of tumour-agnostic therapies represents both a major opportunity for patients to receive therapies targeted to their specific disease on a molecular level and an important step towards discovering biomarkers of response.
Whitepaper Aug 4, 2021
Navigating the Post-COVID Landscape
In this paper we highlight several key themes and recommendations that are essential to consider when navigating our new market environment post COVID-19.
Whitepaper Mar 19, 2021